A Randomised, Double-blind, Placebo-controlled, Dose-escalation, Parallel-group, Single and Multiple Dosing Trial of NN90-1170 in Healthy Volunteers and Patients With Type 2 Diabetes to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics

Novo Nordisk A/S1 site in 1 country24 target enrollmentAugust 1999

ConditionsDiabetes Diabetes Mellitus, Type 2 Healthy

Interventionsliraglutide placebo

Drugsliraglutide placebo

Overview

Phase: Phase 1
Intervention: liraglutide
Conditions: Diabetes
Sponsor: Novo Nordisk A/S
Enrollment: 24
Locations: 1
Primary Endpoint: Area under the Curve
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This trial is conducted in Europe. The aim of this trial is to assess the safety and tolerability (maximum tolerated dose) after single and multiple doses of NNC 90-1170 (liraglutide) in healthy volunteers and in subjects with type 2 diabetes.

Registry

clinicaltrials.gov

Start Date

August 1999

End Date

November 1999

Last Updated

2 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Novo Nordisk A/S

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•HEALTHY VOLUNTEERS
•Healthy subjects aged 18-45 years inclusive
•Healthy subjects are defined as individuals free from significant cardiac, pulmonary, gastrointestinal, hepatic, renal, haematological, neurological and psychiatric disease as determined by history, physical examination and clinical laboratory test results
•Women who are not of childbearing potential
•Signed and dated written informed consent obtained
•Body mass index (BMI) within the range 19-30 kg/m\^2, inclusive
•SUBJECTS WITH DIABETES
•Subjects aged 40-70 years inclusive
•Subjects diagnosed with type-2 diabetes and a duration of diabetes of more than 12 months
•Women who are not of childbearing potential

Exclusion Criteria

•HEALTHY VOLUNTEERS
•Clinically relevant abnormal history or physical findings (e.g. cancer) at the screening assessment, which could interfere with the objectives of the study or the safety of the subject's participation
•Clinically relevant abnormalities of laboratory values or ECG at the screening evaluation
•Presence of acute or chronic illness sufficient to invalidate the subject's participation in the study or to make it unnecessarily hazardous
•Blood pressure and heart rate in seated position at the screening examination outside the ranges 90-150 mmHg systolic, 40-90 mmHg diastolic: heart rate 40-100 beats/min
•History of drug or alcohol abuse (alcohol abuse is defined as intake of more than 28 units weekly in men and more than 21 units weekly in women)
•Alcohol intake within 48 hours prior to visit
•Evidence of drug abuse on urine testing at study entry
•The subject smokes 10 cigarettes or more, or the equivalent, per day and is unable to refrain from smoking during 3 days prior to the first dosing day and during the confinement period
•Hepatitis B surface antigen (HBsAg), Hepatitis C antibodies or HIV (human immunodeficiency virus) antibodies